Compare Gilead Sciences, Inc. (GILD) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X Uranium ETF — how do they compare? Gilead Sciences, Inc. trades at $136.4 (market cap $163.51B), while Global X Uranium ETF trades at $39.01. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Global X Uranium ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| GILD | URA | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $61.81 |
52-Week Low | $108.22 | $36.45 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
The Global X Uranium ETF (URA) is trading at $38.99, down 6.16% over 24 hours amid a bearish technical signal. The fund's technical indicators show moving averages are unanimously bearish while oscillators are neutral, with RSI levels suggesting potential oversold conditions. Recent news highlights URA's position at the intersection of AI-driven power demand and nuclear energy growth, though the ETF faces competition from more focused uranium mining funds.
URA's outlook is supported by structural tailwinds including AI data center electricity needs and government nuclear initiatives, but near-term performance faces headwinds from technical selling pressure and investor preference for pure-play uranium exposure. The fund's 0.52% expense ratio remains higher than energy sector alternatives, creating a valuation challenge relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
